Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • VISTA a Potential New Immuno-Oncology Target in Acute Myeloid Leukemia | Blood | American Society of Hematology (ashpublications.org)
  • Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
  • Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
  • Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
  • Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Post placeholder image
July 14, 2021 in Kineta Press Release

Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506

Kineta Inc 4 Like Post Comments Off on Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506

Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 Seattle, WA — (July 14, 2021) Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announce ...

Read More

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • about
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2023 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean